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Aspirin and Nonsteroidal Anti-Inflammatory Drugs
Can Prevent Cutaneous Squamous Cell Carcinoma:
a Systematic Review and Meta-Analysis
Chiho Muranushi1, Catherine M. Olsen2, Nirmala Pandeya1,2 and Ade`le C Green2,3
Nonsteroidal anti-inflammatory drugs (NSAIDS) have received increasing attention as potential chemopreventive
agents of skin cancer, but evidence is inconsistent. To investigate whether the use of aspirin and other NSAIDS
reduces the risk of squamous cell carcinoma (SCC), we conducted a systematic review on the basis of published
epidemiologic studies and calculated summary estimates for aspirin, nonaspirin NSAIDS, and any NSAIDS use.
Summary estimates from nine studies (five case–control, three cohort, and one intervention) indicated
significantly reduced risks of SCC among users of nonaspirin NSAIDS (relative risk (RR) 0.85, 95% confidence
interval (CI) 0.78–0.94) and among users of any NSAIDS (RR 0.82, 95% CI 0.71–0.94) compared with nonusers with
the effect seen particularly in those with previous actinic skin tumors. A reduced risk was also observed among
aspirin users, although with borderline statistical significance (RR 0.88 95% CI 0.75–1.03). There was significant
heterogeneity between studies regarding SCC risk estimates for aspirin use and any NSAIDS use. These findings
suggest that NSAIDS collectively have the potential to prevent the development of cutaneous SCC.
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INTRODUCTION
Cutaneous squamous cell carcinoma (SCC) is one of the most
frequently occurring malignancies worldwide, and in white
populations SCC presents a significant public health burden
(Lucas et al., 2008). Aspirin and other nonsteroidal
anti-inflammatory drugs (NSAIDS) have received much
attention as potential chemopreventive agents for various
cancers such as colon, breast, lung, and prostate cancers
(Harris et al., 2005); however, evidence in relation to skin
cancer is inconsistent.
It is plausible that NSAIDS protect against SCC because,
chronic exposure to UV radiation, the main cause of SCC
(Armstrong and Kricker, 2001), damages skin cells resulting in
the release of multiple factors including cyclooxygenase
(COX)-2 enzyme and its product, prostaglandin E2, that have
key roles in inflammation (Fecker et al., 2007; Rundhaug
et al., 2011). These factors also influence skin carcinogenesis
(Aggarwal et al., 2009; Maverakis et al., 2010). Overexpression
of COX-2 is consistently found in SCC of the skin (Buckman
et al., 1998; Athar et al., 2001; Kuzbicki et al., 2011). NSAIDS
inhibit COX-2 and suppress production of prostaglandins
(Rundhaug et al., 2011) and thus may have chemopreventive
effects on cutaneous SCC. A topical NSAID, diclofenac, has
been shown to be an effective treatment for actinic keratoses
(Rivers and McLean, 1997; Martin and Stockfleth, 2012), but
consistent evidence of an association between oral NSAIDS
use including aspirin and SCC of the skin is lacking. A rando-
mized controlled trial (RCT) reported a 60% reduced risk of
SCC with the use of a COX-2 inhibitor, celecoxib: Elmets
(2010), whereas a recent case–control study reported an
increased risk of SCC with the use of aspirin or other NSAIDS
(Asgari et al., 2010). A past meta-analysis that included studies
published up to September 2012 reported no association
between the use of any NSAIDS (aspirin and other NSAIDS
were not distinguished) and SCC (pooled relative risk 0.86,
95% confidence interval (Cl) 0.73–1.02; Zhang et al., 2014).
However, there have been a number of recent relevant
published epidemiological studies that this analysis did not
include. To definitively answer the question whether the use of
aspirin and of nonaspirin NSAIDS can reduce the risk of
developing cutaneous SCC, we systematically reviewed all
relevant published studies and synthesized the evidence
available on the topic.
RESULTS
Study selection and study characteristics
The collective search terms identified 286 papers (Figure 1).
After 49 duplicates were removed, 237 titles and abstracts
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were reviewed and 11 full articles were retrieved for review
(Butler et al., 2005; Cook et al., 2005; Grau et al., 2006;
Clouser et al., 2009; Asgari et al., 2010; Elmets et al., 2010;
Amari et al., 2011; Nunes et al., 2011; Torti et al., 2011; Jeter
et al., 2012; Johannesdottir et al., 2012). Two reports
identified did not contain sufficient information to meet the
inclusion criteria (Cook et al., 2005; Amari et al., 2011), as
one reported an effect estimate for keratinocyte cancers
collectively (Amari et al., 2011), and the second reported
estimates for total cancer and some major cancers excluding
SCC (Cook et al., 2005), leaving nine studies providing
detailed data for inclusion in the meta-analysis. All nine
reported a risk estimate of the association between aspirin or
nonaspirin NSAIDS and histologically confirmed SCC
(Tables 1 and 2), and all were published in English. One
study was a RCT (Elmets et al., 2010), three were cohort
(Clouser et al., 2009; Nunes et al., 2011; Jeter et al., 2012),
and the remaining five were case–control studies (Butler et al.,
2005; Grau et al., 2006; Asgari et al., 2010; Torti et al., 2011;
Johannesdottir et al., 2012). In all studies, the case definition
was newly diagnosed SCC and potential confounding factors
were accounted for either by matching or by adjustment.
Quality assessment
Six of the nine studies included in the meta-analysis were
considered to be of high quality (Butler et al., 2005; Clouser
et al., 2009; Asgari et al., 2010; Elmets et al., 2010; Torti et al.,
2011; Jeter et al., 2012), the remaining three studies of low-to-
moderate quality (Grau et al., 2006; Nunes et al., 2011;
Johannesdottir et al., 2012; Supplementary Table 1).
Use of aspirin
Six studies provided estimates for the association between
aspirin use and SCC: three cohort studies (Clouser et al., 2009;
Nunes et al., 2011; Jeter et al., 2012) and three case–control
studies (Asgari et al., 2010; Torti et al., 2011; Johannesdottir
et al., 2012). One cohort and one case-control study studies
reported a significantly reduced risk of SCC with aspirin use
(Nunes et al., 2011; Johannesdottir et al., 2012).
Adjusted estimates for ever-use of aspirin ranged from 0.70
to 0.98 in the cohort studies and from 0.75 to 1.38 in the
case–control studies (Table 2). The overall summary estimate
for ever-use of aspirin compared with nonuse was 0.88 (95%
CI 0.75–1.03) with significant heterogeneity (P¼0.017;
Figure 2) (Table 3). The pooled effect estimate did not differ
according to the study design, or method of exposure assess-
ment, although it tended to be lower in studies conducted
mostly among male study populations or among people at
high risk of skin cancer than among the general population, or
in lower quality studies (Table 3). There was no evidence of
publication bias (P-values for Begg 1.000 and Egger 0.854;
Supplementary Figure 1 and Supplementary Table 2).
Use of nonaspirin NSAIDS
Seven studies, one RCT (Elmets et al., 2010), three cohort
(Clouser et al., 2009; Nunes et al., 2011; Jeter et al., 2012) and
three case–control (Asgari et al., 2010; Torti et al., 2011;
Johannesdottir et al., 2012) studies, presented estimates for the
association between nonaspirin NSAIDS use and SCC. For
exposure to nonaspirin NSAIDS, two studies used nonselective
NSAIDS (Nunes et al., 2011; Johannesdottir et al., 2012), one
used propionic acid NSAIDS (Torti et al., 2011), and celecoxib
was used in the RCT (Elmets et al., 2010).
The adjusted rate ratio for SCC with nonaspirin NSAIDS use
was 0.42 in the RCT, ranged from 0.79 to 0.92 in the cohort
studies and from 0.84 to 1.19 in the case–control studies
(Table 2). The pooled effect estimate indicated a significant
risk reduction (0.85, 95% CI 0.78–0.94) with no evidence of
heterogeneity (P¼ 0.628; Figure 3; Table 3). The pooled
estimate did not differ by study design or exposure assessment
method (Table 3). There was no evidence of publication bias
(P-values for Begg 0.548 and Egger 0.518; Supplementary
Figure 2 and Supplementary Table 2).
Use of aspirin or nonaspirin NSAIDS
Of the nine studies that presented adjusted estimates of the
association between the use of either aspirin or nonaspirin
NSAIDS and SCC, three (the RCT, one cohort, and one case–
control study) reported significant reductions in risk of SCC
(Elmets et al., 2010; Nunes et al., 2011; Johannesdottir et al.,
2012; Table 2). One study assessed exposure to aspirin only
and adjusted analyses for the use of nonaspirin NSAIDS (Jeter
et al., 2012). The summary estimate of any NSAIDS should be
0.82 (0.71–0.94) with a significant heterogeneity (P-value
0.003; Figure 4; Table 3), but no evidence of publication bias
(P-values for Begg 0.118 and Egger 0.250; Supplementary
Figure 3 and Supplementary Table 2). Studies in those at
higher risk of SCC or where exposure assessment was
based on pharmacy databases tended to show stronger inverse
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Figure 1. Flow diagram of study selection for meta-analysis of the effect of
aspirin or nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDS) on
cutaneous squamous cell carcinoma (SCC).
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associations, although higher-quality studies led toward the
null association (Table 3).
Dose–response analyses
All nine studies evaluated a possible dose–response (including
timing) relationship between either aspirin or nonaspirin
NSAIDS and SCC. Only one study, examining aspirin use
and risk of SCC reported a statistically significant (P¼0.05)
dose–response relationship (Jeter et al., 2012).
DISCUSSION
We found that the use of nonaspirin NSAIDS or any NSAIDS
significantly reduced the risk of developing SCC by 15% and
18%, respectively. A reduced risk of similar magnitude was
also observed among aspirin users, although with borderline
statistical significance. Because of a lack of uniformity of dose
units used in different studies, there were insufficient data to
meta-analyse the dose-dependent (frequency and duration)
relationship between NSAIDS intake and SCC. Although not
consistent with a previous meta-analysis of the association
between NSAIDS use and cutaneous SCC showing a nonsigni-
ficant 14% reduced risk (Zhang et al., 2014), our results accord
with the findings of meta-analyses for other cancers (e.g. of the
colon, breast, lung, and prostate; Harris et al., 2005).
A topical NSAID (diclofenac) is already approved for the
use as a treatment for actinic keratoses in the United States,
Europe, and Australia (McGillis and Fein, 2004), and these
results raise the possibility that oral aspirin or nonaspirin
NSAIDS could be used as chemopreventive agents for
cutaneous SCC also. The hypothesized mechanism of action
is mitigation of the actions of inflammatory cytokines such as
COX-2 and its product prostaglandin E2 in promoting skin
Table 1. Characteristics of the nine studies included in the meta-analysis of aspirin or nonaspirin NSAID use and risk
of cutaneous squamous cell carcinoma
First author
(Published
year)
Study
location
Study
design
Study
duration
Cohort description/source
of cases/controls
Sex
(% male)
Diagnosis
method
Exposure
assessment
Exposure
definition
Elmets et al.,
2010
US RCT 2001–
2006
10–40 Actinic keratoses and a
previous histological diagnosis of
at least one actinic keratosis
and/or keratinocyte carcinoma
(very high risk for SCC)
82% Biopsy Pill counts
at each visit
More than 80%
of pills (calocoxib
200 mg b.i.d.) during
a 9-month period
Jeter et al.,
2012
US Cohort 1980–
2008
Nurses’ Health Study
Female registered nurses
aged 30–55
0% Pathology
record
Questionnaire Past or current use
in most weeks
Nunes et al.,
2011
US Cohort 1998–
2004
Veterans Affairs Topical
Tretinoin Chemoprevention
Trial (at least two keratinocyte
carcinomas on the face or ears
within the 5 years before
enrolment) (high risk for SCC)
98% Biopsy Pharmacy
database
At least one
prescription
Clouser et al.,
2009
US Cohort 1984–
1988
SKICAP-AK Trial (a history
of at least 10 actinic
keratoses; very high risk for SCC)
68% Biopsy Questionnaire More than once
per week during the
follow-up period
Johannesdottir
et al., 2012
Denmark Population-
based case–
control
1991–
2008
Danish Cancer Registry Danish
Civil registration System
45% Database based
on morphology
and histology
Prescription
database
Total of more
than two
prescription
during the entire
study period
Torti et al.,
2011
US Population-
based case–
control
1997–
2000
Case: dermatologist and
pathology laboratories
Control: residents list in
New Hampshire
56% Dermatologist
and pathology
laboratories
Interview At least four times
a week for at least
1 month
Asgari et al.,
2010
US Population-
based case–
control
1994–
2005
Kaiser Permanente
Northern California
members aged 43–85
62% Pathology Questionnaire
(and pharmacy
database)
At least once
a week for at
least 1 year
Butler et al.,
2005
Australia Population-
based case–
control
1992–
1996
Nambour Skin Cancer
Prevention Trial
Randomly selected
residents aged 20–69
44% 95%
Histology
Interview Two or more
times per week
for at least
1 year
Grau et al.,
2006
US Clinic-based
case–
control
1983–
1989
Skin Cancer Prevention Study
(at least one histologically
confirmed BCC or SCC after
1 January 1980; high risk for SCC)
40% Biopsy Questionnaire At least one
positive
answer in three
questionnaires
(current use)
Abbreviations: BCC, basal cell carcinoma; NSAID, nonsteroidal anti-inflammatory drug; RCT, randomized controlled trial; SCC, squamous cell carcinoma.
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Table 2. Summary of published results on aspirin or nonaspirin NSAID use and risk of cutaneous squamous cell
carcinoma
First author
(published year) Cases
Cohort size/
controls Type of drugs RR (95% CI) Adjusted factors
RCT
Elmets et al., 2010 NA1 240 NSAIDS2 0.42 (0.19–0.93) Age, sex, Fitzpatrick skin type, actinic
keratosis history at screening, skin cancer
history, and log-transformed patient
time on study
Cohort studies
Jeter et al., 2012 ASA: 1,337
NSAIDS: 1,123
ASA: 92,125
NSAIDS: 76,181
ASA
NSAIDS
0.98 (0.86–1.13)
0.92 (0.75–1.12)
Age, questionnaire cycle, reaction of skin
to sun exposure, ability to tan, number
of severe sunburns, number of moles on
left arm, family history of melanoma, UV-B
availability at state of residence,
menopausal status, and use of
postmenopausal hormones, height, BMI,
physical activity, intake of vitamin C from
foods, intake of vitamin D from foods and
supplements ASA is also adjusted for
smoking status. NSAIDs are also adjusted
for the use of aspirin and acetaminophen
Nunes et al., 2011 309 1,051 ASA
NSAIDS3
NþA
0.70 (0.55–0.88)
0.82 (0.64–1.04)
0.64 (0.52–0.77)
Age, number prior BCC, number
prior SCC, and the Charlson
Comorbidity Index
Clouser et al., 2009 146 1,402 ASA
NSAIDS
NþA
0.711 (0.413–1.22)
0.797 (0.466–1.42)
0.697 (0.460–1.06)
Treatment, age, and gender
Case–control studies
Johannesdottir
et al., 2012
1,921 19,163 ASA
NSAIDS3
NþA
0.86 (0.76–0.98)
0.85 (0.75–0.97)
0.85 (0.76–0.94)
Charlson Comorbidity Index score,
the use of systemic glucocorticoids,
cytostatic or immunosuppressive medication,
and drugs with pigmenting adverse effects
Torti et al., 2011 535 462 ASA
NSAIDS4
NþA
0.75 (0.55–1.02)
1.19 (0.51–2.79)
0.78 (0.59–1.03)
Age, sex, number of cigarettes smoked
per day, skin type, lifelong number
of painful sunburns and lifelong cumulative
number of hours of sun exposure
Asgari et al., 2010 415 415 ASA
NSAIDS
NþA
1.38 (0.96–1.97)
0.84 (0.56–1.26)
1.32 (0.92–1.89)
Eye color, natural hair color, skin type,
education. History of sunburns, history of
high-risk exposures such as UV light, burn
scar, nonhealing ulcers, radiation treatment,
arsenic exposure, exposures to industrial
chemicals, history of smoking, history of
freckling, outdoor sun exposure,
occupational sun exposure, tanning
bed use, and family history of skin cancer
Butler et al., 2005 86 187 NþA 0.65 (0.37–1.14) Skin color, tanning ability, occupation,
clinical solar elastosis, hip or knee pain,
and sunscreen intervention arm of trial
Grau et al., 2006 132 1,019 NþA 0.85 (0.67–1.07) Age, sex, center, risk set time, number of
skin cancers before study entry, skin type,
and total number of questionnaires completed
Abbreviations: ASA, acetylsalicylic acid (aspirin); BCC, basal cell carcinoma; BMI, body mass index; CI, confidence interval; COX, cyclooxygenase; NþA, any
use of aspirin and/or nonaspirin NSAIDs combined; NSAID, nonsteroidal anti-inflammatory drugs; RR, relative risk.
1The mean number of tumors per patient is presented instead of number of incidence.
2Celecxib.
3Nonselective NSAIDS.
4Propionic acid NSAIDS.
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carcinogenesis. Overexpression of COX-2 has been observed
in actinic keratoses and SCC lesions (Muller-Decker et al.,
1999; Kuzbicki et al., 2011), which suggests that COX-2 is
involved in the multiple stages of skin tumorigenesis, and
NSAIDS may thus inhibit this inflammatory pathway
(Subongkot et al., 2003; Guadagni et al., 2007).
NSAIDS appeared to reduce SCC risk to a greater degree in
people with a high prevalence of actinic keratoses or a history
of keratinocyte cancers than in the general population. This
suggests that COX-2 or prostaglandins may also help decrease
the multiplicity of new primary skin cancers in susceptible
people.
Strengths and limitations
This meta-analysis was based on a comprehensive literature
review and included examination of heterogeneity on the
Author and year
Jeter et al. (2012)
Nunes et al. (2011)
Clouser et al. (2009)
Johannesdottir et al. (2012)
Torti et al. (2010)
Asgari et al. (2010)
Overall (I-squared = 63.7%, P = 0.017)
Effect
estimate (95% CI)
%
Weight
0.98 (0.86, 1.13)
0.70 (0.55, 0.88) 18.00
0.71 (0.41, 1.22) 6.54
25.28
13.89
11.65
100.00
0.86 (0.76, 0.98)
0.75 (0.55, 1.02)
1.38 (0.96, 1.97)
24.64
NOTE : Weights are from random effects analysis
0.413 1 2.42
0.88 (0.75, 1.03)
Figure 2. Forest plot of the association between aspirin use and squamous cell carcinoma (studies denoted by first author and publication year).
Table 3. Meta-analysis results using a random effects model: association of aspirin or nonaspirin NSAIDS use and
cutaneous SCC
Aspirin Nonaspirin NSAIDS Any aspirin/nonaspirin NSAID use
Studies RR (95% CI) I2 (%) P het Studies RR (95% CI) I2 (%) P het Studies RR (95% CI) I2 (%) P het
All studies 6 0.88 (0.75–1.03) 64% 0.017 7 0.85 (0.78–0.94) 0% 0.628 9 0.82 (0.71–0.94) 65% 0.003
Study type
Cohort 3 0.82 (0.62–1.07) 70% 0.037 3 0.87 (0.75–1.01) 0% 0.736 3 0.77 (0.56–1.07) 85% 0.001
Case–control 3 0.94 (0.71–1.24) 72% 0.028 3 0.86 (0.76–0.97) 0% 0.742 5 0.87 (0.75–1.01) 42% 0.140
Population studied
General 4 0.94 (0.79–1.11) 65% 0.037 4 0.87 (0.79–0.97) 0% 0.808 5 0.91 (0.78–1.05) 57% 0.055
High1 and very high2 2 0.70 (0.57–0.87) 0% 0.959 3 0.75 (0.56–1.00) 20% 0.286 4 0.70 (0.57–0.86) 41% 0.168
Exposure assessment
Pharmacy database 2 0.80 (0.65–0.97) 56% 0.131 2 0.84 (0.75–0.95) 0% 0.798 2 0.75 (0.57–0.99) 84% 0.013
Self-report 4 0.95 (0.74–1.20) 61% 0.054 4 0.90 (0.76–1.07) 0% 0.864 6 0.89 (0.76–1.05) 48% 0.086
Quality assessment
High 4 0.95 (0.74–1.20) 61% 0.054 5 0.87 (0.73–1.04) 4% 0.384 6 0.84 (0.67–1.06) 62% 0.023
Low 2 0.80 (0.65–0.97) 56% 0.131 2 0.84 (0.75–0.95) 0% 0.798 3 0.78 (0.65–0.93) 69% 0.040
Abbreviations: CI, confidence interval; NSAID, nonsteroidal anti-inflammatory drug; RR, relative risk; SCC, squamous cell carcinoma.
1All participants: a history of skin cancer.
2All participants: a high prevalence (410) of actinic keratoses).
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basis of various study characteristics as well as an evaluation
of study quality. Compared with the previous meta-analysis
(Zhang et al., 2014), which examined only the association
between any NSAID use and SCC, our review included two
further studies (Butler et al., 2005; Nunes et al., 2011) and our
more comprehensive combined estimates included data from
four additional studies for any NSAID use, two additional
studies for aspirin use, and four additional studies for
nonaspirin NSAID use. Seven of the nine studies included in
our review adjusted for reported sun exposure either directly
or indirectly (by adjusting for past history of skin cancer),
which is important as sun exposure is the primary cause of
cutaneous SCC (IARC Working Group on the Evaluation of
Carcinogenic Risks to Humans, 2012). The definition of
aspirin and nonaspirin NSAIDS use varied across studies,
however, with participants categorized as temporary or infre-
quent ‘‘users’’ in some studies being regarded as ‘‘nonusers’’
in other studies. As a result, the prevalence of use varied
widely across studies, ranging from 23 to 77% for ever-use of
aspirin or nonaspirin NSAIDS. In addition, referent groups
were not consistent across studies, with some defining
nonusers as those who took neither aspirin nor nonaspirin
NSAIDS, whereas others included aspirin users in the referent
group while estimating the effect of nonaspirin NSAIDS and
vice versa without adjusting for the other exposure. Overall,
however, there was no major difference in risks of SCC among
these user subgroups both within studies or in aggregate.
Heterogeneity in the prevalence of NSAID use across studies
Author and year
Effect
estimate (95% Cl)
0.42 (0.19, 0.93)
0.92 (0.75, 1.12)
0.82 (0.64, 1.04)
0.80 (0.45, 1.42)
0.85 (0.78, 0.94)
0.84 (0.56, 1.26)
1.19 (0.51, 2.79)
0.85 (0.75, 0.97)
1.39
21.76
14.84
2.61
52.88
1.21
5.32
100.00
%
Weight
Elmets et al. (2010)
Jeter et al. (2012)
Nunes et al. (2011)
Clouser et al. (2009)
Johannesdottir et al. (2012)
Torti et al. (2010)
Asgari et al. (2010)
Overall (I-squared = 0.0%, P = 0.628)
NOTE: Weights are from random effects analysis
0.19 1 5.26
Figure 3. Forest plot of the association between nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDS) use and squamous cell carcinoma (studies denoted
by first author and publication year).
Author and year
Effect
estimate (95% Cl)
0.42 (0.19, 0.92)
0.98 (0.86, 1.13)
0.64 (0.52, 0.77)
0.70 (0.46, 1.06)
0.85 (0.76, 0.94)
0.78 (0.59, 1.03)
0.82 (0.71, 0.94)
0.85 (0.67, 1.07)
0.65 (0.37, 1.14)
1.32 (0.92, 1.89)
2.75
17.61
14.95
7.36
18.85
11.53
8.84
4.80
13.31
100.00
%
Weight
Elmets et al. (2010)
Jeter et al. (2012)
Nunes et al. (2011)
Clouser et al. (2009)
Johannesdottir et al. (2012)
Torti et al. (2010)
Asgari et al. (2010)
Bulter et al. (2005)
Grau et al. (2006)
Overall (I-squared = 65.4%, P = 0.003)
NOTE: Weights are from random effects analysis
0.19 1 5.26
Figure 4. Forest plot of the association between any aspirin or nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDS) use and squamous cell carcinoma
(studies denoted by first author and publication year).
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may have reflected the different proportions of participants
with health conditions associated with NSAID use (e.g.,
arthritis and coronary heart disease), which in turn could
have affected study outcomes through associations with
immune system function or sun exposure. We were unable
to fully assess the relationship between different doses of
aspirin or NSAIDS and SCC. In the studies of aspirin use, for
example, high and low doses were not analyzed separately in
four of the six relevant studies, despite the different inherent
mechanisms involved. Low-dose aspirin has an antiplatelet
effect by reducing production of thromboxane A2 by COX-1
inhibition, whereas high-dose aspirin has an anti-inflammatory
effect by reducing the production of prostaglandin E2 by COX-
2 inactivation (Vane et al., 1998). In addition, all nonaspirin
NSAIDS were regarded as being the same in our analyses even
though different nonaspirin NSAIDS have different kinetics
and dynamics (Moore, 2002) and therefore may have quite
different effects on risk. Finally, accuracy of exposure
assessment in the included studies could be questioned: self-
report is known to be inaccurate for non-repetitive NSAIDS
use (West et al., 1995), whereas prescription databases lack
information on the use of common over-the-counter NSAIDS
(Srensen et al., 2001).
In conclusion, synthesis of existing published data supports
a significant inverse association between oral NSAIDS use and
incidence of cutaneous SCC, particularly among people with a
high prevalence of actinic keratoses or a history of keratinocyte
cancers. Further research is required that not only accounts for
participants’ sun exposure but that also includes accurate
assessment of NSAIDS dosages and information about the
reasons for NSAID use in order to evaluate the association of
NSAIDS (aspirin in particular) and SCC in greater details.
MATERIALS AND METHODS
This systematic review was conducted and reported according to the
PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) statement as a guideline (http://www.prisma-statement.org/).
There was no previously published protocol.
Search strategy
We searched the PubMed, Web of Science, and EMBASE databases,
using the search terms ‘‘nsaids’’, ‘‘aspirin’’, ‘‘cyclooxygenase’’,
‘‘nonmelanoma’’, ‘‘non-melanoma’’, ‘‘squamous cell carcinoma’’,
‘‘skin’’, ‘‘cutaneous’’, ‘‘case-control’’, ‘‘cohort’’, ‘‘trial’’, and ‘‘inci-
dence’’. A single reviewer identified all potentially relevant studies
published in any language to February 2014. Titles and abstracts of
articles were reviewed to exclude laboratory-based or therapeutic
studies, reviews, and duplicate publications; full-texts of the remain-
ing articles were obtained. The reference lists of reviews and retrieved
articles and ‘‘Related citations’’ in PubMed and ‘‘Times cited’’ in Web
of Science for relevant articles were checked. All reasons for exclud-
ing studies were recorded. Study criteria were discussed with the
other investigators and disagreements were resolved by consensus.
Eligibility criteria
Only case–control, cohort, or intervention studies that examined oral
intake of aspirin or nonaspirin NSAIDS in relation to risk of cutaneous
SCC were considered. To be included, the studies had to report RR or
odds ratio (OR) with 95% CI or provide sufficient data to permit these
calculations. If multiple publications evaluated the same or highly
overlapped study populations, only the one with the most relevant
and comprehensive data (e.g., most recently published or largest
sample size) was included.
Data extraction and quality assessment
Extracted data included first author and year of publication, study
location, design and duration, source of study population and sex
distribution of participants, type of NSAID used (aspirin and/or
nonaspirin NSAIDS or a specific NSAID), and exposure assessment
(self-report or prescription-based pharmacy database), method of
diagnosis (pathology, self-report or registry), total sample size,
numbers of exposed cases and non-cases, adjusted effect estimates
with lower and upper 95% CIs, and adjusted factors in the analyses.
Studies were classified by sampling frame (general population,
participants with a history of skin cancer (defined as ‘‘high risk’’),
participants with higher prevalence (410) of actinic keratoses
(defined as ‘‘very high risk’’)), exposure assessment (prescription
database, self-report), diagnosis method (histology, cancer registry,
other (self-report or not mentioned)), results of quality assessment (low
or high), and types of anti-inflammatory drugs (aspirin only, NSAIDS
excluding aspirin, any NSAIDS).
We evaluated the quality of the studies by using a scoring system
that was designed with reference to the following guidelines: Meta-
analysis Of Observational Studies in Epidemiology (MOOSE; Stroup
et al., 2000), Quality Assessment Tool for Systematic reviews of
Observational studies (QATSO; Wong et al., 2008), and Streng-
thening the Reporting of Observational Studies in Epidemiology
(STROBE; von Elm et al., 2007). Studies were assessed on three
aspects––namely study design, method of assessment of exposure to
aspirin or nonaspirin NSAIDS, and whether important confounding
effects were taken into account during analysis. Two points were
allocated for study design, with two points given for cohort studies or
RCTs, one point for population-based case–control studies and no
points for clinic-based case–control studies. Studies that assessed
exposure based on pill counts or personal recall were allocated one
point and those based on pharmacy databases scored 0 points.
Studies adjusted for age and sex they received one point, if they
were additionally adjusted for a measure of pigmentation or skin type
they received two points, and if they also adjusted for a measure of
sun exposure they received three points. A total score of 4–6 was
considered high quality and 1–3 low-moderate quality.
Statistical analysis
To obtain the pooled estimate, we used a random effects meta-
analysis model to account for heterogeneity between the studies
(DerSimonian and Laird, 1986). Statistical heterogeneity among
studies was explored using a Cochrane Q test for heterogeneity
(Cochran, 1954). We also calculated I2 value (ranging from 0%
indicating no observed heterogeneity to 100%) to examine the degree
of heterogeneity due to between-study variability (Higgins et al.,
2003). To identify publication bias toward studies showing positive
rather than null results, a funnel plot (Begg and Mazumdar, 1994) was
constructed and the Egger regression asymmetry test (Egger et al.,
1997) applied. Sensitivity analyses were conducted by removing
individual studies one at a time from the pooled analysis and
examining their influence on the pooled estimate. Analyses were
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performed by drug types (aspirin, nonaspirin NSAIDS, and any
NSAIDS). For studies where RRs or ORs were reported for various
doses but not for ever-use, the estimates for ever-use were calculated
by combining the dose effect using RREst9 (Kinoshita et al., 2002).
When effect estimates for nonselective and selective NSAIDS were
reported separately, the estimates of nonselective NSAIDS were used.
When studies separately reported results for aspirin and nonaspirin
NSAIDS for the same study population, we included the results with
the larger sample size in analyses of the use of aspirin or nonaspirin
NSAIDS to avoid double-counting people who used both aspirin and
NSAIDS.
Subgroup analysis
Analyses were performed to assess the consistency of associations
between aspirin and nonaspirin NSAIDS and SCC within certain
prespecified subgroups: study design (cohort vs. case–control), study
population (general vs. high and very high risked), exposure assess-
ment method (prescription database vs. self-report), and quality of the
individual studies (high vs. low). All statistical analyses were per-
formed with the software STATA version 10.0 (Stata corporation,
College Station, TX, USA). All P-values were two-tailed.
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